136 completed, 14 unknown, 8 withdrawn, 7 terminated. 52 Phase 4, 46 Phase 3, 30 Phase 2, 23 Phase 1, 19 Not applicable.
Follow Glycopyrrolate: new trials by email Literature Review of Glycopyrrolate trials Research Report on Glycopyrrolate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Fluticasone/Formoterol/Glycopyrronium for the Treatment Chronic Obstructive Pulmonary Disease (TRIPLAR) Fluticasone 250mcg/Formoterol 12mcg/Glycopyrronium 25mcg, Comparator - Trimbow® - Chronic Obstructive Pulmonary Disease | Phase 3 | Not yet recruiting | Eurofarma Laboratorios S.A. | 1252 | 2027-01-30 | 2026-10-26 |
| Phase 1 PK Study of AERO-007, an Inhaled LABA+LAMA Combination for Nebulization Delivery in COPD Patients AERO-002 (60 mcg), Glycopyrrolate (18 mcg) - COPD (Chronic Obstructive Pulmonary Disease) | Phase 1 | Completed | AeroRx Therapeutics Inc. | 24 | 2026-09-21 | 2026-10-15 |
| BETRI-Prospective: Asthma Control in Single Inhaler ICS/LABA/LAMA (87/5/9 pMDI [BDP/FF/GB - 100/6/12.5 μg]) vs Single Inhaler ICS/LABA (200/6 pMDI [BDP/FF - 200/6 μg]) Beclometasone dipropionate, formoterol fumarate, and glycopyrronium bromide (100/6/12.5 µg per actuation), Foster® 200/6 pMDI (BDP/FF-200/6 µg) - Asthma | Phase 4 | Recruiting | Chiesi Farmaceutici S.p.A. | 644 | 2026-06-28 | 2026-07-31 |
| A Phase II Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Single Inhaled Doses of Ensifentrine-glycopyrrolate Fixed Dose Combination, Ensifentrine, and Glycopyrrolate in Subjects With Chronic Obstructive Pulmonary Disease Ensifentrine 3 mg, Glycopyrrolate 42.5 mcg, Ensifentrine 1.5 mg - Chronic Obstructive Pulmonary Disease | Phase 2 | Completed | Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA | 33 | 2025-10-06 | 2026-01-08 |
| Clinical Study of Ensifentrine-Glycopyrrolate (MK-5884A/RPL554) Fixed-dose Combination Dose Ranging in Participants With COPD (MK-5884A-029/RPL554-CO-212) Ensifentrine 3 mg, Glycopyrrolate 21.25 mcg, Glycopyrrolate 42.5 mcg - Chronic Obstructive Pulmonary Disease | Phase 2 | Completed | Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA | 497 | 2025-07-31 | 2026-09-11 |
| Early Screening of Young COPD and Pre-COPD Budesonide, Glycopyrronium Bromide and Formoterol Fumarate Inhalation Aerosol - Pulmonary Disease, Chronic Obstructive | Not yet recruiting | yanmengkang | 100 | 2025-03-01 | 2025-02-25 | |
| Fixed Triple Inhaled Combination in Asthmatic Patients in a Real-life Setting BDP/FF/G (Beclomethasone diprprionate, formoterol fumarate, glycopyrronium bromide) 172/5/9 μg - Asthma, Asthma Patients | Completed | Chiesi Bulgaria | 281 | 2025-02-01 | 2026-03-19 | |
| Fixed Triple Inhaled Combination in Asthmatic Patients in a Real-life Setting (STRENGTH) BDP/FF/G (beclometasone dipropionate/formoterol fumarate dihydrate/glycopyrronium) 172/5/9 μg - Asthma, Asthma Patients | Recruiting | Chiesi Slovenija, d.o.o. | 200 | 2024-11-04 | 2026-03-24 | |
| Investigation of Fixed Triple Inhaled Combination in Asthmatic Patients, in a Real-life Setting BDP/FF/G (Beclomethasone diprprionate, formoterol fumarate, glycopyrronium bromide) 172/5/9 μg - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Asthma Bronchiale | Recruiting | Chiesi Hungary Ltd. | 800 | 2024-10-24 | 2024-11-22 | |
| A Phase IIb Study of Glycopyrrolate Inhalation Solution Over 1 Week in Subjects With COPD Glycopyrrolate (85 μg), Glycopyrrolate (42.5 μg), Glycopyrrolate (14 μg) - Chronic Obstructive Pulmonary Disease | Phase 2 | Completed | Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA | 46 | 2024-08-16 | 2026-02-09 |
| Sugammadex v.s. Neostigmine/Glycopyrrolate Group S: sugammadex injection, Group N: neostigmine/glycopyrrolate - Head and Neck Surgery, Chronic Sinusitis | Not applicable | Completed | National Taiwan University Hospital | 124 | 2024-05-01 | 2025-09-12 |
| Change in Patient-repOrted Outcomes in COPD Patients Newly Initiated on TRIXEO AEROSPHERE in Real worlD budesonide / glycopyrronium / formoterol - Chronic Obstructive Pulmonary Disease (COPD) | Completed | AstraZeneca | 10 | 2024-04-30 | 2025-12-22 | |
| A RCT to Compare the Effectiveness of Nebulized Anticholinergics for Cough Suppression During Flexible Bronchoscopy Glycopyrronium, Ipratropium, Saline - Subjects Undergoing Flexible Bronchoscopy | Phase 2 / Phase 3 | Unknown | Post Graduate Institute of Medical Education and Research, Chandigarh | 1050 | 2024-04-24 | 2024-04-22 |
| Neuromuscular Blockade Comparison for GI-2 Recovery After Bowel Resection Neostigmine Injectable Solution, Sugammadex injection - Intestinal Disease | Phase 4 | Completed | University of California, Irvine | 132 | 2024-04-17 | 2026-08-25 |
| Comparative Efficacy of Once-daily LAMA/LABA Combinations Versus Tiotropium on Constant-work-rate Cycle Endurance in COPD Tiotropium, Olodaterol, Umeclidinium - COPD (Chronic Obstructive Pulmonary Disease) | Not applicable | Suspended | Medical University of Bialystok | 100 | 2024-03-11 | 2026-10-02 |
| ANTES B+ Clinical Trial Trelegy Ellipta 100/62.5/25Mcg Inh 30D, Brimica, Duaklir - Chronic Obstructive Pulmonary Disease | Phase 4 | Terminated | Fundacio Privada Mon Clinic Barcelona | 48 | 2024-02-29 | 2025-08-14 |
| IKANOS: Breztri Maintenance Versus Any Non-Triple Inhaled Therapy After Hospitalization for a COPD Exacerbation in the US Budesonide/glycopyrrolate/formoterol fumarate (Breztri Aerosphere) 320 μg/18 μg/9.6 μg administered as two inhalations, twice daily., External Comparator - COPD | Phase 4 | Withdrawn | AstraZeneca | 2024-01-19 | 2024-02-01 | |
| The Impact of Sugammadex on Ileus After Abdominal Wall Reconstruction Neostigmine / Glycopyrrolate, Sugammadex - Hernia, Ventral, Ileus | Phase 4 | Completed | Clayton Petro | 184 | 2024-01-15 | 2025-11-21 |
| A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a Next-Generation Propellant in Participants 40 to 80 Years of Age With COPD BGF MDI HFO 320/14.4/9.6μg, BGF MDI HFA 320/14.4/9.6 μg, Placebo MDI HFA - COPD (Chronic Obstructive Pulmonary Disease) | Phase 3 | Completed | AstraZeneca | 297 | 2024-01-11 | 2025-08-27 |
| Neostigmine/Glyco-pyrrolate 50 Mikrogram/kg or Sugammadex 2 mg/kg for Reversal of Neuromuscular Blockade in Elderly Patients neostigmine/glycopyrrolate, Sugammadex - Neuromuscular Blockade, Residual | Phase 4 | Completed | Matias Vested | 40 | 2023-12-04 | 2025-08-26 |
Showing 20 of 174. Sign in to see all of them.
Pulmonary Disease, Chronic Obstructive (81) · Asthma (12) · Neurogenic Bowel (6) · Spinal Cord Injuries (6) · Hyperhidrosis (5) · Bradycardia (4) · Constipation (4) · Lung Diseases (4) · Respiratory Tract Diseases (4) · Encopresis (3) · Fecal Incontinence (3) · Lung Diseases, Obstructive (3) · Postoperative Nausea and Vomiting (3) · Respiratory Aspiration (3) · Sialorrhea (3)
Novartis Pharmaceuticals (34) · Chiesi Farmaceutici S.p.A. (12) · Merck Sharp & Dohme LLC (9) · Pearl Therapeutics, Inc. (9) · James J. Peters Veterans Affairs Medical Center (7) · AstraZeneca (6) · Novartis (6) · Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA (3) · B.P. Koirala Institute of Health Sciences (2) · Dr. August Wolff GmbH & Co. KG Arzneimittel (2) · Jie Chen (2) · Orion Corporation, Orion Pharma (2) · Seoul National University Hospital (2) · Sunovion Respiratory Development Inc. (2) · The Cleveland Clinic (2)
United States (69) · Germany (28) · Canada (19) · Hungary (19) · United Kingdom (19) · Spain (17) · Belgium (16) · Poland (16) · South Korea (16) · France (13) · Russia (13) · Bulgaria (12) · China (11) · Denmark (10) · Netherlands (10)
Colin Reisner, MD (5) · Dave Singh, MD (4) · Christopher P Cardozo, MD (3) · Chadwick Orevillo (2) · Don Cockcroft, MD (2) · Guangyou Duan, doctor (2) · He Huang, MD (2) · Adriana Rodriguez, MD (1) · Anthony Kovac, MD (1) · Arvi Yli-Hankala, MD (1) · Asish Subedi, MD (1) · Ben L Olesnicky, BMBS BSc (1)
PMID 24156566, PMID 28821260, PMID 31539467, PMID 32021148, PMID 32450869, PMID 33152467, PMID 35815359, PMID 10365009, PMID 10861154, PMID 11573596, PMID 17054153, PMID 18385265, PMID 18389982, PMID 18946293, PMID 19218369, PMID 19713265, PMID 19859776, PMID 20416390, PMID 20495139, PMID 20541381, PMID 20683334, PMID 20809967, PMID 20956145, PMID 20978028, PMID 21632228, PMID 22151296, PMID 22323952, PMID 22459983, PMID 22780437, PMID 22973092, PMID 23060624, PMID 23155808, PMID 23217058, PMID 2400072, PMID 24321804, PMID 24347351, PMID 24429126, PMID 24438744, PMID 24534204, PMID 24596459, PMID 25208233, PMID 25501602, PMID 25609942, PMID 25841237, PMID 25906190, PMID 25935840, PMID 26177074, PMID 26254585, PMID 26549785, PMID 26991619
2009 (5), 2017 (4), 2023 (4), 2008 (2), 2014 (1), 2019 (1), 2025 (1), U01HL128952 (1)